Skip to content
10-Q

Quarterly Report

Atea Pharmaceuticals, Inc. AVIR

0001193125-26-219678

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 11, 2026 80.03M sh
Shares Diluted Q1 2026 · Mar 31, 2026 79.2M sh
Shares Diluted Q1 2026 · Mar 31, 2025 85.16M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$46.39M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$30.56M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $79.32M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $95.71M
Stockholders Equity Q1 2026 · Mar 31, 2026 $233.71M
Stockholders Equity Q1 2026 · Dec 31, 2025 $275.43M
Stockholders Equity Q1 2026 · Mar 31, 2025 $411.08M
Stockholders Equity Q1 2026 · Dec 31, 2024 $438.87M
Current Liabilities Q1 2026 · Mar 31, 2026 $33.37M
Current Liabilities Q1 2026 · Dec 31, 2025 $39.78M
Current Assets Q1 2026 · Mar 31, 2026 $263.2M
Current Assets Q1 2026 · Dec 31, 2025 $310.99M
Total Assets Q1 2026 · Mar 31, 2026 $267.08M
Total Assets Q1 2026 · Dec 31, 2025 $315.22M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.57
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.40
Eps Basic Q1 2026 · Mar 31, 2026 −$0.57
Eps Basic Q1 2026 · Mar 31, 2025 −$0.40
Sga Expense Q1 2026 · Mar 31, 2026 $6.87M
Sga Expense Q1 2026 · Mar 31, 2025 $9.46M
Rd Expense Q1 2026 · Mar 31, 2026 $41.13M
Rd Expense Q1 2026 · Mar 31, 2025 $29.58M
Net Income Q1 2026 · Mar 31, 2026 −$45.44M
Net Income Q1 2026 · Mar 31, 2025 −$34.27M
Operating Income Q1 2026 · Mar 31, 2026 −$48.01M
Operating Income Q1 2026 · Mar 31, 2025 −$39.04M